Detalhe da pesquisa
1.
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
N Engl J Med
; 386(1): 24-34, 2022 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34986285
2.
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Lancet Oncol
; 24(1): 33-44, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36460017
3.
COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.
Future Oncol
; 19(16): 1091-1098, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37309702
4.
Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial.
Br J Cancer
; 127(4): 695-703, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35610366
5.
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
N Engl J Med
; 381(7): 626-636, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166680
6.
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group.
Cancer Immunol Immunother
; 71(2): 327-337, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34164709
7.
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
Future Oncol
; 18(8): 903-913, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35073733
8.
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 395(10240): 1835-1844, 2020 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-32534646
9.
Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review.
BMC Gastroenterol
; 21(1): 227, 2021 May 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34011268
10.
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 21(11): 1465-1477, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32961119
11.
Prognosis and Management of BRAF V600E-Mutated Pregnancy-Associated Melanoma.
Oncologist
; 25(8): e1209-e1220, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32271498
12.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
N Engl J Med
; 377(19): 1824-1835, 2017 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28891423
13.
Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?
Cancer Immunol Immunother
; 69(8): 1549-1564, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32303794
14.
A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors.
Oncologist
; 24(8): e755-e764, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31073024
15.
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.
Cancer Immunol Immunother
; 68(5): 765-772, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30806748
16.
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 19(10): 1315-1327, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30219628
17.
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol
; 19(5): 603-615, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29573941
18.
Nivolumab in previously untreated melanoma without BRAF mutation.
N Engl J Med
; 372(4): 320-30, 2015 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-25399552
19.
CDKN2A/CDK4 Status in Greek Patients with Familial Melanoma and Association with Clinico-epidemiological Parameters.
Acta Derm Venereol
; 98(9): 862-866, 2018 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29774366
20.
MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortium.
J Eur Acad Dermatol Venereol
; 32(12): 2134-2141, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30098061